ABIVAX Société Anonyme (ABVX) Stock Overview

A clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. More details

ABVX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 75.5% below our estimate of its fair value

Earnings are forecast to grow 64.05% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the US market

ABVX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW494,834 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

494,834 investors already sharing narratives

View all narratives

ABIVAX Société Anonyme Competitors

Price History & Performance

Summary of share price highs, lows and changes for ABIVAX Société Anonyme
Historical stock prices
Current Share Price	€135.98
52 Week High	€148.83
52 Week Low	€8.11
Beta	-0.21
1 Month Change	40.84%
3 Month Change	8.09%
1 Year Change	1,439.98%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	1,538.31%

Recent News & Updates

Seeking Alpha • Jun 30

Abivax: Latest Obefazimod Data Eases Safety Fears, Brings M&A Back Into Play

Summary ABIVAX Société Anonyme surged >35% on positive Phase 3 data for obefazimod in ulcerative colitis, reinforcing its differentiated, multi-pathway mechanism and best-in-class profile. Recent safety data alleviated cancer concerns, with malignancy rates consistent with UC background and no expected boxed warning, supporting a clear regulatory path. Obefazimod’s efficacy and oral administration position ABVX as a serious competitor to established immunology drugs, with potential $4bn annual sales in a ~$30bn market. I see at least 30% further upside if obefazimod secures U.S. approval, with M&A speculation offering >120% potential based on rumored acquisition prices. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jun 30

Abivax: Latest Obefazimod Data Eases Safety Fears, Brings M&A Back Into Play

Seeking Alpha • Mar 27

ABIVAX: Undercovered, Late-Stage French Company With Upcoming Catalysts

Summary ABIVAX is a French company that IPO-ed in the US in 2023 and is running a phase 3 trial for ulcerative colitis. Their lead candidate, obefazimod, is in phase 3 trials for moderate to severe ulcerative colitis and has a novel mechanism of action. The company faces competition from other approved treatments for ulcerative colitis, but their drug has shown promising efficacy and a good safety profile. Read the full article on Seeking Alpha

Shareholder Returns

	ABVX	US Biotechs	US Market
7D	-5.6%	-2.0%	0.1%
1Y	1,440.0%	34.9%	20.3%

Return vs Industry: ABVX exceeded the US Biotechs industry which returned 34.9% over the past year.

Return vs Market: ABVX exceeded the US Market which returned 20.3% over the past year.

Price Volatility

Is ABVX's price volatile compared to industry and market?
ABVX volatility
ABVX Average Weekly Movement	20.0%
Biotechs Industry Average Movement	10.3%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.2%

Stable Share Price: ABVX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ABVX's weekly volatility has decreased from 84% to 20% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2013	80	Marc M. de Garidel	www.abivax.com

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

ABIVAX Société Anonyme Fundamentals Summary

How do ABIVAX Société Anonyme's earnings and revenue compare to its market cap?
ABVX fundamental statistics
Market cap	US$11.78b
Earnings (TTM)	-US$378.14m
Revenue (TTM)	US$5.60m

2,104x

P/S Ratio

-31.2x

P/E Ratio

Is ABVX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABVX income statement (TTM)
Revenue	€4.92m
Cost of Revenue	€0
Gross Profit	€4.92m
Other Expenses	€337.12m
Earnings	-€332.20m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Sep 21, 2026

Earnings per share (EPS)	-3.85
Gross Margin	100.00%
Net Profit Margin	-6,752.03%
Debt/Equity Ratio	7.6%

How did ABVX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/13 01:03
End of Day Share Price	2026/07/13 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ABIVAX Société Anonyme is covered by 21 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Etzer Darout	Barclays
Julian Harrison	BTIG
Jason Butler	Citizens JMP Securities, LLC

ABIVAX Société Anonyme (ABVX) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

ABIVAX Société Anonyme Competitors

BioMarin Pharmaceutical

Exelixis

Ionis Pharmaceuticals

Apogee Therapeutics

Price History & Performance

Recent News & Updates

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of $800 million.

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of $600 million.

Abivax: Latest Obefazimod Data Eases Safety Fears, Brings M&A Back Into Play

Abivax Reports Positive Abtect Maintenance Part 2 Results for Obefazimod in Refractory Ulcerative Colitis Patients

Abivax Reports Landmark Phase 3 Abtect Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme, Annual General Meeting, May 11, 2026

Recent updates

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of $800 million.

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of $600 million.

Abivax: Latest Obefazimod Data Eases Safety Fears, Brings M&A Back Into Play

Abivax Reports Positive Abtect Maintenance Part 2 Results for Obefazimod in Refractory Ulcerative Colitis Patients

Abivax Reports Landmark Phase 3 Abtect Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme, Annual General Meeting, May 11, 2026

ABIVAX Société Anonyme Announces Board and Management Changes

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease At Ecco 2026

ABIVAX Société Anonyme to Report First Half, 2026 Results on Sep 14, 2026

ABIVAX Société Anonyme to Report Fiscal Year 2025 Results on Mar 23, 2026

Abivax SA Presents 22 Abstracts On Obefazimod In Inflammatory Bowel Disease At ECCO 2026 Including Oral Presentation On Preclinical Anti-Fibrotic Findings

Abivax SA Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of $649.984 million.

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of $400 million.

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, Its First-In-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis

Abivax Sa Announces Completion of Enrollment for the Phase 3 Abtect Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Abivax SA Appoints Dominik Höchli to the Board of Directors

ABIVAX: Undercovered, Late-Stage French Company With Upcoming Catalysts

ABIVAX Société Anonyme, Annual General Meeting, Jun 06, 2025

ABIVAX Société Anonyme to Report Q1, 2025 Results on Jun 02, 2025

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Abivax SA Announces Resignation of Philippe Pouletty as Director, Effective December 31, 2024

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme to Report Fiscal Year 2023 Results on Apr 02, 2024

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

Shareholder Returns

Price Volatility

About the Company

ABIVAX Société Anonyme Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources